Herpes zoster ophthalmicus in Olmsted County, Minnesota: Have systemic antivirals made a difference?

Archives of Ophthalmology

Volumn 121, Issue 3, 2003, Pages 386-390

  Severson, Erik A ^a,c   Baratz, Keith H ^b   Hodge, David O ^b   Burke, James P ^b  

^a MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF NORTH DAKOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; CORTICOSTEROID; VALACICLOVIR;

ADULT; AGED; ANTIVIRAL ACTIVITY; ARTICLE; CORNEA EPITHELIUM; DISEASE SEVERITY; DRUG EFFECT; FEMALE; HERPES ZOSTER OPHTHALMICUS; HUMAN; KERATITIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; VIRUS REACTIVATION; VIRUS SHEDDING; VISUAL ACUITY;

EID: 0037337704     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.121.3.386     Document Type: Article

References (36)

1. Hyman RW, Ecker JR, Tenser RB. Varicella-zoster virus RNA in human trigeminal ganglia. Lancet. 1983;2:814-816.
2. Marsh RJ, Fraunfelder FT, McGill JI. Herpetic corneal epithelial disease. Arch Ophthalmol. 1976;94:1899-1902.
3. Liesegang TJ. Corneal complications from herpes zoster ophthalmicus. Ophthalmology. 1985;92:316-324.
4. Cobo M, Foulks GN, Liesegang T, et al. Observations on the natural history of herpes zoster ophthalmicus. Curr Eye Res. 1987;6:195-199.
5. Edgerton AE. Herpes zoster ophthalmicus. Arch Ophthalmol. 1945;34:40-153.
6. Scheie HG. Herpes zoster ophthalmicus. Trans Ophthalmol Soc U K. 1970;90:899-929.
7. Womack LW, Liesegang TJ. Complications of herpes zoster ophthalmicus. Arch Ophthalmol. 1983;101:42-45.
8. Pavan-Langston D, McCulley JP. Herpes zoster dendritic keratitis. Arch Ophthalmol. 1973;89:25-29.
9. de Haas EBH. Desiccation of cornea and conjunctiva after sensory denervation: significance of desiccation for pathogenesis of neuroparalytic keratitis. Arch Ophthalmol. 1962;67:79-92.
10. Naumann G, Gass JDM, Font RL. Histopathology of herpes zoster ophthalmicus. Am J Ophthalmol. 1968;65:533-541.
11. Hedges TR, Albert DM. The progression of the ocular abnormalities of herpes zoster. Ophthalmology. 1982;89:165-177.
12. Willerson D Jr, Aaberg TM, Reeser FH. Necrotizing vaso-occlusive retinitis. Am J Ophthalmol. 1977;84:209-219.
13. Culbertson WW, Blumenkranz MS, Haines H, et al. The acute retinal necrosis syndrome, II: histopathology and etiology. Ophthalmology. 1982;89:1317-1325.
14. Pratesi R, Freeman FR, Lowry JL. Herpes zoster ophthalmicus with contralateral hemiplegia. Arch Neurol. 1977;34:640-641.
15. Gilbert GJ. Herpes zoster ophthalmicus and delayed contralateral hemiparesis: relationship of the syndrome to central nervous system granulomatous angiitis. JAMA. 1974;229:302-304.
16. Dolin R, Reichman RC, Mazur MH, et al. Herpes zoster-varicella infections in immunosuppressed patients. Ann Intern Med. 1978;89:375-388.
17. Nasr AM, Beyer-Machule CK, Yeatts RP. Cicatricial ectropion secondary to herpes zoster. Ophthalmic Surg. 1983;14:763-765.
18. Ragozzino MW, Melton LJ, Kurland LT, et al. Population-based study of herpes zoster and its sequelae. Medicine (Baltimore). 1982;61:310-316.
19. Bean B, Braun C, Balfour HH Jr. Acyclovir therapy for acute herpes zoster. Lancet. 1982;2:118-121.
20. McGill J, MacDonald DR, Fall C, et al. Intravenous acyclovir in acute herpes zoster infection. J Infect. 1983;6:157-161.
21. McKendrick MW, McGill JI, White JE, et al. Oral acyclovir in acute herpes zoster. Br Med J (Clin Res Ed). 1986;293:1529-1532.
22. Balfour HH Jr, Bean B, Laskin DL, et al. Acyclovir halts progression of herpes zoster in immunocompromised patients. N Engl J Med. 1983;308:1448-1453.
23. Tyring S, Barbarash RA, Nahlik JE, et al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and post-herpetic neuralgia; a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1995;123:89-96.
24. Cobo LM, Foulks GN, Liesegang TJ, et al. Oral acyclovir in the treatment of acute herpes zoster ophthalmicus. Ophthalmology. 1986;93:763-770.
25. Harding SP, Porter SM. Oral acyclovir in herpes zoster ophthalmicus. Curr Eye Res. 1991;10(suppl):177-182.
26. Hoang-Xuan T, Buchi ER, Herbort CP, et al. Oral acyclovir for herpes zoster ophthalmicus. Ophthalmology. 1992;99:1062-1070.
27. Herbort CP, Buechi ER, Piguet B, et al. High-dose oral acyclovir in acute herpes zoster ophthalmicus. Curr Eye Res. 1991;10(suppl):171-175.
28. Aylward GW, Claoue CMP, Marsh RJ, et al. Influence of oral acyclovir on ocular complication of herpes zoster ophthalmicus. Eye. 1994;8:70-74.
29. Kubeyinje EP. Cost-benefit of oral acyclovir in the treatment of herpes zoster. Int J Dermatol. 1997;36:457-459.
30. Melton LJ. History of the Rochester Epidemiology Project. Mayo Clin Proc. 1996;71:266-274.
31. Liesegang TJ. Epidemiology of ocular herpes simplex: natural history in Rochester, Minnesota, 1950 through 1982. Arch Ophthalmol. 1989;107:1160-1165.
32. Erie JC, Nevitt MP, Hodge DD, et al. Incidence of ulcerative keratitis in a defined population from 1950 through 1988. Arch Ophthalmol. 1993;111:1665-1671.
33. Kennedy RH, Brubaker RF. Traumatic hyphema in a defined population. Am J Ophthalmol. 1988;106:123-130.
34. Baratz KH, Gray DT, Hodge DO, et al. Cataract extraction rates in Olmsted County, Minnesota, 1980 through 1994. Arch Ophthalmol. 1997;115:1441-1446.
35. Bartley GB, Fatourechi V, Kadrmas EF, et al. Long-term follow-up of Graves ophthalmopathy in an incidence cohort. Ophthalmology. 1996;103:958-962.
36. International Classification of Diseases, Ninth Revision, Clinical Modification. Washington, DC: Public Health Service, US Dept of Health and Human Services; 1988.